Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Breast Cancer Treatment Market: By Drug Class, By Distribution Channel, and Geography
Breast Cancer Treatment Market size was valued at US$ 33.20 billion in 2022, growing at a CAGR of 7.9% from 2022-29. Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. Breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease.
Study Period
2024-2030Base Year
2023CAGR
7.9%Largest Market
North AmericaFastest Growing Market
Asia Pacific
The global breast cancer treatment market is expected to increase with significant CAGR due to increasing prevalence and incidence of breast cancer cases. Rising awareness about breast cancer stages and treatment, government initiatives, and improving healthcare infrastructure are driving the breast cancer treatment market. Moreover, the rise in the healthcare expenditure, increase in the diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco, and rising female population age of 65 years and above are expected to fuel the market over the forecast period.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2022 |
US$ 33.20 billion |
Market CAGR |
7.9% |
By Drug Class |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The breast cancer treatment market key players are: Novartis AG, Pfizer Inc., AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Viatris Inc., Zydus Lifesciences Limited, Teva Pharmaceutical Industries Ltd., and F. Hoffmann-La Roche Ltd
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1. Executive Summary |
2. Global Breast Cancer Treatment Market Introduction |
2.1. Global Breast Cancer Treatment Market - Taxonomy |
2.2. Global Breast Cancer Treatment Market -Definitions |
2.2.1. By Treatment |
2.2.2. By Cancer Type |
2.2.3. By Distribution Channel |
3. Global Breast Cancer Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Breast Cancer Treatment Market Dynamic Factors - Impact Analysis |
3.6. Global Breast Cancer Treatment Market - Competition Landscape |
4. Global Breast Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
2.1. Global Breast Cancer Treatment Market - Taxonomy |
2.1. Global Breast Cancer Treatment Market - Taxonomy |
2.1. Global Breast Cancer Treatment Market - Taxonomy |
5. Global Breast Cancer Treatment Market, By Treatment, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1. Immunotherapy |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Chemotherapy |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Targeted Treatment |
5.3.1. Abemaciclib |
5.3.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.1.3. Market Opportunity Analysis |
5.3.2. Ado-Trastuzumab Emtansine |
5.3.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.2.3. Market Opportunity Analysis |
5.3.3. Everolimus |
5.3.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3.3. Market Opportunity Analysis |
5.3.4. Olaparib |
5.3.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.4.3. Market Opportunity Analysis |
5.3.5. Palbociclib |
5.3.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.5.3 Market Opportunity Analysis |
5.3.6. Pertuzumab |
5.3.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.6.3. Market Opportunity Analysis |
5.3.7. Ribociclib |
5.3.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.7.3. Market Opportunity Analysis |
5.3.8. Trastuzumab |
5.3.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.8.3. Market Opportunity Analysis |
5.3.9. Others |
5.3.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.3.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.9.3. Market Opportunity Analysis |
5.4. Hormonal Treatment |
5.4.1. Aromatase Inhibitors |
5.4.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.1.3. Market Opportunity Analysis |
5.4.2. Estrogen Receptor Downregulators (ERDs) |
5.4.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.2.3. Market Opportunity Analysis |
5.4.3. Selective Estrogen Receptor Modulators (SERMs) |
5.4.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
5.4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3.3. Market Opportunity Analysis |
6. Global Breast Cancer Treatment Market Forecast, By Cancer Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1. HER2+ |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Hormone Receptor |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Breast Cancer Treatment Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1. Hospital |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Pharmacies |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Others |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. Global Breast Cancer Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Region, 2023 - 2029 |
9. North America Breast Cancer TreatmentMarketAnalysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
9.1. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Flat Rolled |
9.1.2. Immunotherapy |
9.1.3. Chemotherapy |
9.1.4. Targeted Treatment |
9.1.4.1. Abemaciclib |
9.1.4.2. Ado-Trastuzumab Emtansine |
9.1.4.3. Everolimus |
9.1.4.4. Trastuzumab |
9.1.4.5. Ribociclib |
9.1.4.6. Palbociclib |
9.1.4.7. Pertuzumab |
9.1.4.8. Olaparib |
9.1.4.9. Others |
9.1.5. Hormonal Treatment |
9.1.5.1. Aromatase Inhibitors |
9.1.5.2. Estrogen Receptor Downregulators (ERDs) |
9.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
9.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.2.1. HER2+ |
9.2.2. Hormone Receptor |
9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
9.3.1. Hospital |
9.3.2. Retail Pharmacies |
9.3.3. Online Pharmacies |
9.3.4. Pharmacies |
9.3.5. Others |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country, 2023 - 2029 |
9.6. North America Breast Cancer Treatment Market Dynamics - Trends |
10. Europe Breast Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
10.1. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Flat Rolled |
10.1.2. Immunotherapy |
10.1.3. Chemotherapy |
10.1.4. Targeted Treatment |
10.1.4.1. Abemaciclib |
10.1.4.2. Ado-Trastuzumab Emtansine |
10.1.4.3. Everolimus |
10.1.4.4. Trastuzumab |
10.1.4.5. Ribociclib |
10.1.4.6. Palbociclib |
10.1.4.7. Pertuzumab |
10.1.4.8. Olaparib |
10.1.4.9. Others |
10.1.5. Hormonal Treatment |
10.1.5.1. Aromatase Inhibitors |
10.1.5.2. Estrogen Receptor Downregulators (ERDs) |
10.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
10.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.2.1. HER2+ |
10.2.2. Hormone Receptor |
10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
10.3.1. Hospital |
10.3.2. Retail Pharmacies |
10.3.3. Online Pharmacies |
10.3.4. Pharmacies |
10.3.5. Others |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Poland |
10.4.8. Rest of Europe |
10.5. Europe Breast Cancer Treatment Market - Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2023 - 2029 |
10.6. Europe Breast Cancer Treatment Market Dynamics - Trends |
11. Asia-Pacific Breast Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
11.1. Treatment Analysis 2018 - 2022 and Forecast 2023 - 2029by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Flat Rolled |
11.1.2. Immunotherapy |
11.1.3. Chemotherapy |
11.1.4. Targeted Treatment |
11.1.4.1. Abemaciclib |
11.1.4.2. Ado-Trastuzumab Emtansine |
11.1.4.3. Everolimus |
11.1.4.4. Trastuzumab |
11.1.4.5. Ribociclib |
11.1.4.6. Palbociclib |
11.1.4.7. Pertuzumab |
11.1.4.8. Olaparib |
11.1.4.9. Others |
11.1.5. Hormonal Treatment |
11.1.5.1. Aromatase Inhibitors |
11.1.5.2. Estrogen Receptor Downregulators (ERDs) |
11.1.5.3. Selective Estrogen Receptor Modulators (SERMs) |
11.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
11.2.1. HER2+ |
11.2.2. Hormone Receptor |
11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
Key Market Players